ONO PHARMACEUTICAL CO

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: $7.1B

Website: https://www.ono.co.jp/

Clinical Trials

Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: ONO-4538
Drug: Placebo

First Posted Date: 2014-10-17

Last Posted Date: 2024-05-03

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 493

Registration Number: NCT02267343

Locations: 🇨🇳
Kaohsiung Clinical Site, Kaohsiung, Taiwan
🇯🇵
Chiba Clinical Site, Chiba, Japan
🇯🇵
Ehime Clinical Site, Matsuyama, Ehime, Japan

and more 23 locations

ONO-4538 Phase I Study in Patients With Solid Tumor

Phase 1

Completed

Conditions: Advanced Solid Tumors
Recurrent Solid Tumors

Interventions: Drug: ONO-4538

First Posted Date: 2014-10-10

Last Posted Date: 2024-05-06

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 18

Registration Number: NCT02261285

Locations: 🇰🇷
Seoul Clinical Site 104, Seoul, Korea, Republic of
🇰🇷
Seongnam-si Clinical Site 105, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul Clinical Site 103, Seoul, Korea, Republic of

and more 2 locations

ONO-4538 Phase I Study in Patients With Solid Tumor

Phase 1

Completed

Conditions: Advanced Solid Tumors
Recurrent Solid Tumors

Interventions: Drug: ONO-4538

First Posted Date: 2014-10-10

Last Posted Date: 2024-05-03

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 18

Registration Number: NCT02261298

Locations: 🇰🇷
Seongnam-si Clinical Site 105, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul Clinical Site 101, Seoul, Korea, Republic of
🇰🇷
Seoul Clinical Site 102, Seoul, Korea, Republic of

and more 2 locations

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Advanced Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: ONO-4538

First Posted Date: 2014-06-26

Last Posted Date: 2024-12-09

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 104

Registration Number: NCT02175017

Locations: 🇰🇷
Ulsan Clinical Site 105, Ulsan, Korea, Republic of
🇰🇷
Incheon Clinical Site 102, Incheon, Korea, Republic of
🇰🇷
Seongnam-si Clinical Site 104, Seongnam-si, Gyeonggi-do, Korea, Republic of

and more 7 locations

A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)

Phase 2

Completed

Conditions: Ocular Hypertension
Open Angle-glaucoma

Interventions: Drug: ONO-9054
Drug: Latanoprost

First Posted Date: 2014-03-11

Last Posted Date: 2016-02-25

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 123

Registration Number: NCT02083289

Locations: 🇺🇸
Pasadena Clinical Site, Pasadena, California, United States
🇺🇸
New York Clinical Site, New York, New York, United States
🇺🇸
Morrow Clinical Site, Morrow, Georgia, United States

and more 9 locations

A Human Mass Balance Study to Determine the Total Recovery of Radioactivity in Urine and Faeces Following a Single Oral Dose of 14C Radiolabelled ONO-4053

Phase 1

Completed

Conditions: Healthy Adult Male Subjects

Interventions: Drug: [14C]ONO-4053

First Posted Date: 2013-07-29

Last Posted Date: 2014-04-15

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 8

Registration Number: NCT01909986

Locations: 🇬🇧
Nottingham Clinical site, Nottingham, United Kingdom

Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis

Phase 2

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: High dose ONO-4053
Drug: Low dose ONO-4053
Drug: Placebo
Drug: Cetirizine

First Posted Date: 2012-12-12

Last Posted Date: 2014-04-15

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 58

Registration Number: NCT01748344

Locations: 🇦🇹
Vienna Clinical Site, Vienna, Austria

A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease

Phase 1

Completed

Conditions: GERD

Interventions: Other: Placebo
Drug: ONO-8539

First Posted Date: 2012-10-16

Last Posted Date: 2015-10-14

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 14

Registration Number: NCT01707901

Locations: 🇬🇧
London Clinical site, London, United Kingdom
🇧🇪
Leuven Clinical site, Leuven, Belgium

A Study to Investigate the Effect of ONO-8539 on Acid-Induced Oesophageal Hypersensitivity in Healthy Volunteers

Phase 1

Completed

Conditions: Acid Reflux

Interventions: Other: Placebo
Drug: ONO-8539

First Posted Date: 2012-10-12

Last Posted Date: 2014-07-08

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 20

Registration Number: NCT01705275

Locations: 🇬🇧
London Clinical site Recruiting, London, United Kingdom

A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: ONO-4053
Drug: Placebo

First Posted Date: 2012-02-23

Last Posted Date: 2012-12-10

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 80

Registration Number: NCT01537172

Locations: 🇬🇧
Hammersmith Medicines Research Ltd, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy